Professional Media briefs

Elsevier announced a new partnership with the Canadian Cardiovascular Society, which includes the publication of the Canadian Journal of Cardiology, an established title. Elsevier will begin publishing the journal in January 2011. The Canadian Cardiovascular Society, a professional association, has over 19,000 members.

Research published in the Public Library of Science (PLoS) Medicine concluded that the publication of industry-supported drug trials was associated with an increase in journal impact factors, namely, an increase in sales. The article's authors found that sales of reprints may provide “substantial income,” and called for journals to disclose financial information by the same standards that authors must, so that “readers can assess the potential effect of different types of papers on a journals' revenue and impact,” according to an abstract of the research.

San Lucas Medical Limited, a London-based print and online publisher of 15 medical journals in Europe and Asia, partnered with Medikly, a digital and social media firm. The partnership will allow San Lucas Medical to quickly distribute content among physicians, and will provide tools for real-time collaboration.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.